Replimune Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REPL research report →
Range $19 – $31
Price Chart
About the company
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells.
- CEO
- Sushil Patel
- IPO
- 2018
- Employees
- 465
- HQ
- Woburn, MA, US
Get TickerSpark's AI analysis on REPL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.81B
- P/E
- -6.89
- Fwd P/E
- 114.88
- PEG
- -0.26
- P/S
- 0.00
- P/B
- 9.88
- EV/EBITDA
- -6.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -157.78%
- ROIC
- -80.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-319,919,000
- Net Income
- $-313,940,000-26.9%
- EPS
- $-3.38-10.1%
- OCF Growth
- -45.8%
- FCF Growth
- -43.0%
- 52W High
- $23.54
- 52W Low
- $1.50
- 50D MA
- $15.22
- 200D MA
- $10.25
- Beta
- 0.93
- RSI (14)
- 54
- Avg Volume
- 2.49M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Replimune’s quarter was pre-revenue but marked by an encouraging early launch of TUDRIQEV, with broad coverage, fast formulary uptake, and management sounding optimistic about adoption.· October 28, 2026
- No product revenue was recorded this quarter because first commercial shipments happened in early October; Replimune expects first product revenue in fiscal Q3.
- R&D was $34.4 million, SG&A was $21.9 million, and net loss was $57.1 million; cash and cash equivalents were $307.8 million at quarter-end.
- Management said more than 70% of the initial 200 target accounts had been proactively engaged, about 20 accounts had placed TUDRIQEV on formulary, and over 15 institutions had written at least one prescription.
- Coverage appears to be building quickly, with NCCN Category 2A guidance, many commercial payer policies covering to label, Medicare coverage established, and no volume restrictions mentioned.
- The company said it has more than a year of inventory on hand, is nearly fully staffed commercially, and plans to continue expanding beyond the initial 200 accounts.
Replimune reported no product revenue in fiscal Q2 because first commercial shipments occurred in early October. Research and development expense was $34.4 million versus $49.3 million in fiscal Q1, selling, general and administrative expense was $21.9 million versus $19.0 million in fiscal Q1, and net loss was $57.1 million versus $69.8 million in the prior quarter. The company ended the quarter with $307.8 million in cash and cash equivalents, including $141 million in net proceeds from its August offering; it said that cash should fund operations for greater than 12 months. Management did not provide revenue guidance, but said TUDRIQEV’s list price is $450,000 per course before rebates and discounts and that first product revenue should be reported in fiscal Q3.
Sushil Patel framed the launch of TUDRIQEV as a defining moment and the first commercial product from Replimune’s RPx platform. He emphasized that the broad label matches real-world physician use, that there is clear unmet need in PD-1-refractory melanoma, and that early demand has been strong. He also highlighted supply readiness, with more than a year of inventory on hand, and said the commercial team has been rebuilt and rightsized to execute.
Emily Hill said the quarter was a pre-revenue period because commercial shipments began only in early October, and she pointed to the expense build from launch preparations. She quantified R&D at $34.4 million, SG&A at $21.9 million, and cash at $307.8 million after including $141 million of net proceeds from the August offering. She also said the current operating plan, including TUDRIQEV launch spending and continued funding of IGNYTE-3, should support operations for greater than 12 months, and she declined to provide revenue guidance at this time.
Analysts focused on launch cadence, account readiness, physician workflow bottlenecks, prescription-to-dose timing, and how to think about patient volume and pricing. Management said the main gating items are operational rather than clinical, with accounts moving through formulary, workflow setup, and ordering at different speeds; they gave examples of treatment occurring very quickly after ordering. On formulary and access, they said policies are broadly aligned with label, there are no volume restrictions in the published policies, and some accounts are bypassing usual review to treat patients faster.
The call showed early commercial traction: more than 70% of the initial 200 target accounts were engaged, about 20 accounts were on formulary, and over 15 institutions had already written prescriptions within less than 20 business days. Management said payer coverage is broad, inventory is ample, and interest is coming from both academic centers and some regional community sites, suggesting the launch may extend beyond the initial adopter base.
The launch is still very early, and management repeatedly said it is too soon to quantify patient volume, average revenue per patient, or differences by lesion type. Revenue has not yet started, first product shipments only began in October, and management declined to provide revenue guidance. They also acknowledged that some institutions move slowly because of internal P&T and workflow processes, and that commercialization still depends on successfully scaling beyond the first wave of accounts.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.0%
- Shares Outstanding
- 94.80M
- Float Shares
- 89.16M
of shares held by institutions
226 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 11.05M | 0 |
| Blackrock, Inc. | 8.80M | ▼ 159.53K |
| Rtw Investments, LP | 7.41M | ▲ 54.66K |
| Ridgeback Capital Investments L.P. | 7.31M | ▲ 7.31M |
| Goldman Sachs Group Inc | 4.54M | ▲ 2.26M |
| Montanova Capital, LLC | 4.39M | ▲ 168.00K |
| State Street Corp | 4.17M | ▼ 265.88K |
| Boxer Capital Management, LLC | 3.98M | ▲ 2.81M |
| Marshall Wace, Llp | 3.82M | ▲ 3.82M |
| Vanguard Group Inc | 3.78M | ▲ 296.80K |
| Vanguard Capital Management LLC | 3.40M | ▲ 499.55K |
| Fcpm Iii Services B.V. | 2.81M | 0 |
Held by 175 ETFs
Biggest fund positions in REPL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Xynos Konstantinos | sell | 16,198 |
| Nov 16, 26 | Schwendenman Andrew | sell | 2,148 |
| Nov 16, 26 | Patel Sushil | sell | 49,026 |
| Nov 16, 26 | Hill Emily Luisa | sell | 14,709 |
| Nov 9, 26 | SLATTERY JOSEPH P | sell | 5,200 |
| Nov 2, 26 | Dhingra Kapil | other | 43,169 |
| Nov 2, 26 | Dhingra Kapil | sell | 21,500 |
| Nov 2, 26 | Dhingra Kapil | other | 43,169 |
| Aug 20, 26 | Astley-Sparke Philip | other | 50,000 |
| Aug 17, 26 | Hill Emily Luisa | sell | 9,256 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our REPL coverage
Recent articles, reports, and earnings notes.
No research on REPL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REPL report →Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
zacks.com · Nov 18
REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
zacks.com · Nov 12
Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
benzinga.com · Nov 11
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
zacks.com · Nov 2
Replimune: 3 Key Takeaways for Long-Term Investors
fool.com · Oct 28
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
seekingalpha.com · Oct 28
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
globenewswire.com · Oct 28
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.